Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor
NCT ID: NCT03087877
Last Updated: 2018-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
70 participants
INTERVENTIONAL
2017-02-03
2017-03-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CGM Users
Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention.
Acetaminophen Challenge (G6 CGM)
Evaluation of acetaminophen effect on CGM glucose sensing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acetaminophen Challenge (G6 CGM)
Evaluation of acetaminophen effect on CGM glucose sensing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of diabetes
Exclusion Criteria
* Known gastroparesis
* Abnormal liver function
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DexCom, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Price, MD
Role: STUDY_DIRECTOR
DexCom, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AMCR
Escondido, California, United States
William Sansum Diabetes Center
Santa Barbara, California, United States
Diablo Clinical Research
Walnut Creek, California, United States
Rainier Clinical Research Center Inc
Renton, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PTL902020
Identifier Type: -
Identifier Source: org_study_id